Dr Peter Sargent
Dr Peter Sargent is Head of Business Development
at the NIHR
Latest articles
COVAX delivers 600,000 vaccines to Ghana in bid for global equality
COVAX has shipped 600,000 doses of the Oxford/AstraZeneca vaccine, from the Serum Institute of India (SII) to Ghana. The arrival in Accra, the capital...
NHS prescription charge to increase from 1 April 2021
The NHS prescription charge will increase to £9.35 per prescription item from 1 April 2021 in England, according to the Pharmaceutical Services Negotiating Committee...
Sanofi and GSK start new study of COVID-19 vaccine
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study with 720 volunteers aged 18 and over to select the...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Nasal spray to protect against COVID-19 is ready for use in humans
A nasal spray to provide protection against the COVID-19 virus has been formulated by researchers at the University of Birmingham, UK, using compounds already...
JCVI updates priority list for COVID-19 vaccine
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that the first priorities for any COVID-19 vaccination programme should be the prevention of...
Sanofi and GSK start new study of COVID-19 vaccine
Sanofi and GlaxoSmithKline (GSK) have announced the initiation of a new Phase II study with 720 volunteers aged 18 and over to select the...